Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kelda M. Gardner
Observed names:
Kelda Gardner,
Kelda M Gardner
Institution:
University of Washington
Observed institutions:
Seattle Cancer Care Alliance,
University of Washington,
University of Washington Medical Center,
Fred Hutch Cancer Center
OpenAlex ID:
A5061565755
CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia
2020
·
Melinda A. Biernacki
, Kimberly A. Foster
, et al.
·
Journal of Clinical Investigation
·
100
PDF
Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
2015
·
Jennifer E. Vaughn
, Megan Othus
, et al.
·
JAMA Oncology
·
50
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
2018
·
Anna B. Halpern
, Megan Othus
, et al.
·
Leukemia
·
49
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow
2020
·
Colin D. Godwin
, Yi Zhou
, et al.
·
Blood
·
45
Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.
2013
·
Roland B Walter
, Lenise R Taylor
, et al.
·
PubMed
·
42
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome
2020
·
Frances Linzee Mabrey
, Kelda M. Gardner
, et al.
·
Blood Advances
·
31
PDF
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
2018
·
Anna B. Halpern
, Megan Othus
, et al.
·
Haematologica
·
29
PDF
G‐CSF P riming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm
2014
·
Pamela S. Becker
, Bruno C. Medeiros
, et al.
·
American Journal of Hematology
·
19
PDF
Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study
2013
·
Tara L. Chen
, Elihu H. Estey
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
14
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
2020
·
Mary-Elizabeth M. Percival
, Megan Othus
, et al.
·
Haematologica
·
5
PDF
E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML
2018
·
Sylvia S Chien
, Jin Dai
, et al.
·
Blood
·
5
Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?
2019
·
Michael Jamie Hochman
, Megan Othus
, et al.
·
Journal of Clinical Oncology
·
4
Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
2022
·
Piyanuch Kongtim
, Mary-Elizabeth M. Percival
, et al.
·
Blood
·
3
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)
2021
·
Michael J. Hochman
, Megan Othus
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
3
Relation between measurable residual disease and morphologic relapse in AML.
2020
·
Lauren Shih
, Megan Othus
, et al.
·
Journal of Clinical Oncology
·
3
Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms
2019
·
Anna B. Halpern
, Megan Othus
, et al.
·
Blood
·
3
Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)
2019
·
Jacob Appelbaum
, Anisha Loeb
, et al.
·
Blood
·
3
Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML)
2013
·
Victor Chow
, Kathleen Shannon Dorcy
, et al.
·
Leukemia Research Reports
·
3
PDF
A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia
2019
·
Pamela S. Becker
, Vivian G. Oehler
, et al.
·
Blood
·
2
Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
2019
·
Mary-Elizabeth M. Percival
, Megan Othus
, et al.
·
Blood
·
2
Need for routine examination of left ventricular ejection fraction in patients with AML
2019
·
Hiba M. Khan
, Kelda M. Gardner
, et al.
·
Leukemia
·
2
Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study
2013
·
Roland B. Walter
, Bruno C. Medeiros
, et al.
·
Blood
·
2
Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia
2020
·
Mallette M. Asmuth
, Anna B. Halpern
, et al.
·
Blood
·
1
Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow
2019
·
Colin D. Godwin
, Yi Zhou
, et al.
·
Blood
·
1
Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
2019
·
Colin D. Godwin
, Megan Othus
, et al.
·
Blood
·
1
Show more works
View as search
Works count:
44
Citation count:
425
H-index:
9
I10-index:
9
Year
Topic
Type
